What if the youngest league MVP in NBA history never blew out his knee? What if the No. 1 pick in the 2002 NBA draft, an ...

Acurx Pharmaceuticals, Inc. ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today ...

Public health officials are concerned that we could move back into a situation like that of the early 20th century, before ...

This marks Zevtera as the sole FDA-approved MRSA-targeting cephalosporin antibiotic for these conditions. It is also indicated for acute bacterial skin and skin structure infections (ABSSSI ...

The history of antibiotic resistance in Staphylococcus aureus spans more than half a century. Methicillin-resistant S. aureus (MRSA) has emerged as an almost ubiquitous pathogen in both the ...

In 1962, the first case of methicillin-resistant Staphylococcus aureus (MRSA) was identified. Resistance of certain bacteria to other antibiotics was also reported. For several decades starting in the ...

Expert Rev Anti Infect Ther. 2013;11(5):499-509. Outbreak strain(s) are given in bold. CA: Community associated; HA: Healthcare associated; MRSA: Methicillin-resistant Staphylococcus aureus; ND ...

MRSA is a type of staph highly resistant to a common class of antibiotics. Many people carry MRSA harmlessly on their skin or inside their noses. However, if the bacteria penetrates the skin ...

Inc., a wholly owned subsidiary of Innoviva Inc., for the commercialization of Basilea’s hospital anti-MRSA antibiotic Zevtera (ceftobiprole) in the United States. Innoviva Specialty Therapeutics is a ...

The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole's revenues, currently a minor part of its CHF 131 million ($137 million ...